Chhattisgarh High Court Grants Bail to Chaitanya Baghel in Alleged Liquor Scam Case || AP HC Restores Arbitral Awards in Hindustan Shipyard Case, Allows Moderation of Exorbitant Damages || J&K&L HC: GST Refund is a Vested Right and Cannot Be Curtailed by Retrospective 2019 Amendment || Cal HC Orders Change of Prosecutor In 2021 Murder Case, Says Accused Cannot Be Detained Indefinitely || P&H HC Cites Bhagavad Gita, Directs Regularisation of Daily Wage Workers For Public Good || Bombay HC Conducts Emergency Hearing from CJ’s Residence as Court Staff Deployed for Elections || Madras HC: Preventive Detention Laws are Draconian, Cannot be Used to Curb Dissent or Settle Politics || HP HC: Mere Interest in a Project Cannot Justify Impleading a Non-Signatory in Arbitration || J&K&L HC: Women Accused in Non-Bailable Offences Form a Distinct Class Beyond Sec 437 CrPC Rigour || Bombay HC Restores IMAX’s Enforcement of Foreign Awards Against E-City, Applying Res Judicata

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :